BPIQ Pipeline Screener Case Study

We used our BPIQ pipeline screener (https://www.bpiq.com/pipeline-screener) to identify companies that might be effected by the upcoming FDA ODAC meeting on April 22, 2022 on PI3K inhibitors in blood cancer. For this task we simply searched the mechanism of action field of our BPIQ pipeline screener for "PI3K". This projects stems from the announcement on Friday by TGTX that it is pulling its Umbralisib-containing blood cancer therapeutics that were conditionally approved by the FDA under an accelerated approval based on prior progression free survival (PFS) data and overall response rate (ORR) data.

We find the following 3 companies with PI3K inbhitors approved or in development for blood cancers, and whose stock price will likely be effected by the FDA ODAC meeting:

#HCM #HMPL-689 (delta)(NHL)(Ph1/2)

#MEIP #Zandelisib (delta)(FLB-cell) (Ph3)

#VSTM #Copiktra (delta/gamma)(CLL, SLL, FL)(app)

And indirectly on point, we find

#INFI #Eganelisib (gamma)(solid tumors)(ph1-3)

and the following that indirectly inhibit a PI3K pathway:

#KZIA #Paxalisib (GDC-0084) (Glio)(Ph2-3)

#LPTX #DKN-01 (solid tumors)(Ph2-3)

#ONTX #Rigosertib (solid tumors)(Ph1-2)